Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Leukemia
Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3-Mutated AML
Read More
Addition of Enasidenib to Azacitidine Improves Response versus Azacitidine Alone in Mutant IDH2 Newly Diagnosed Acute Myeloid Leukemia
Read More
Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine-131-Apamistamab in Patients with Active R/R AML Results in Donor Hematopoietic Cell Engraftment
Read More
Emerging Mutations in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Relapsed on Gilteritinib
Read More
Frontline Selinexor and Chemotherapy Is Highly Active in Older Adults with Acute Myeloid Leukemia
Read More
CLL1-CD33 Compound CAR (cCAR) T-Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia
Read More
Escalated Dosing Schedules of CC-486 Effective for Patients Experiencing First AML Low Blast Count Relapse
Read More
Gilteritinib + Azacitidine or Azacitidine Alone in Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia
Read More
Comparative Effectiveness of Glasdegib or Venetoclax in Combination with Low-Dose Cytarabine Using Simulated Treatment Comparisons
Read More
Phase 1b/2 Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies
Read More
1
2
3
4
5
6
Page 3 of 7
Results 21 - 30 of 64